Fig. 2: CDDD11-8 reduces expression of CDK9 targets.
From: Selective inhibition of CDK9 in triple negative breast cancer
a Representative immunoblots showing the effect of CDDD11-8 on RNA polymerase II (Pol II), phosphorylated RNAP II at Serine 2 in the C-terminal domain (p-Pol II CTD Ser2), MYC, and MCL1 protein expression in TNBC cell lines after 6 h of treatment. GAPDH was used as a loading control. The average densitometry is normalized to GAPDH and presented as relative to vehicle treated cells. b Bar graph of RT‐PCR data for expression of CDK9 target genes MYC and MCL1 after 4 h treatment with CDDD11-8. RT-PCR data was normalized to GAPDH and presented as relative to vehicle. Data represents the mean ± S.E.M. of 3 technical replicates per condition. Data was analysed using a two-way ANOVA (CDDD11-8 concentration F = 394, 160.4, 57.84, and 22.76 for MDA-MB-453, MDA-MB-468, MDA-MB-231, and MFM-223 cells, respectively; d.f. = 2, p < 0.0001 for each test). Asterisks denote a significant difference between treatment and vehicle, as determined using Dunnett’s multiple comparisons test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
